Two-year results from the phase 3 OAKS and DERBY studies evaluating Syfovre for geographic atrophy showed clinically meaningful reduction of lesion growth with increasing effect over time.
The results, published in The Lancet, confirmed the efficacy of Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals) with both monthly and every other month administration in 809 patients vs. 402 sham controls.
“The treatment effects increasing over time in combination with the junctional zone microperimetry analyses demonstrating a positive signal of visual preservation were both meaningful to me,”